The current status of early use of oral β-blockers in patients with acute coronary syndrome and the association with the in-hospital outcomes.
10.3760/cma.j.cn112148-20201118-00917
- Author:
Jun LIU
1
;
Jing LIU
1
;
Yong Chen HAO
1
;
Na YANG
1
;
Meng Ge ZHOU
1
;
Yu Hong ZENG
1
;
Dong ZHAO
1
Author Information
1. Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China.
- Publication Type:Journal Article
- MeSH:
Acute Coronary Syndrome/drug therapy*;
Adrenergic beta-Antagonists/therapeutic use*;
Heart Failure;
Hospitals;
Humans;
Male;
Shock, Cardiogenic
- From:
Chinese Journal of Cardiology
2021;49(9):886-893
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the status of early use of oral β-blocker and its relationship with in-hospital outcomes in eligible patients with acute coronary syndrome (ACS). Methods: The study was based on the Improving Care for Cardiovascular Disease in China (CCC)-ACS project. The data of ACS patients that collected during 2014 to 2019 from 230 collaborating hospitals across China were analyzed. Propensity score matching method and Cox multivariate regression analysis were used to analyze the association between early use of oral β-blocker and in-hospital outcomes within 15 days. Results: A total of 38 663 eligible ACS patients were included in this study. The mean age was (57.0±9.0), and 78.8% of the ACS patients (30 470/38 663) were male. The proportion of early use of oral β-blockers was 64.9% (25 112/38 663), but varied substantially, in the 230 hospitals with a range from 0 to 100%. Compared with the patients no early use of oral β-blocker, the patients receiving early oral β-blocker had significantly lower incidence of major cardiovascular adverse events (MACEs) (3.4% (395/11 536) vs. 2.9%(339/11 536), P=0.036)and less occurrences of heart failure (2.7% (316/11 536) vs. 2.1% (248/11 536), P=0.004). Multivariate Cox regression analyses showed the patients receiving early oral β-blocker had 15.5%, 23.1%, and 35.3% lower risks of MACEs, heart failure and cardiogenic shock respectively than the patients no early oral β-blocker. Conclusions: Compared with the patients no early oral β-blocker, the patients receiving early oral β-blocker had lower risks of MACEs events, heart failure and cardiogenic shock. However, the early use of oral β-blocker in ACS patients was generally insufficient with huge differences among different hospitals in China.
